These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20400095)

  • 1. The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study.
    Li JS; Flynn JT; Portman R; Davis I; Ogawa M; Shi H; Pressler ML
    J Pediatr; 2010 Aug; 157(2):282-7. PubMed ID: 20400095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of eplerenone versus losartan in patients with low-renin hypertension.
    Weinberger MH; White WB; Ruilope LM; MacDonald TM; Davidson RC; Roniker B; Patrick JL; Krause SL
    Am Heart J; 2005 Sep; 150(3):426-33. PubMed ID: 16169319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.
    Weinberger MH; Roniker B; Krause SL; Weiss RJ
    Am J Hypertens; 2002 Aug; 15(8):709-16. PubMed ID: 12160194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension.
    Hollenberg NK; Williams GH; Anderson R; Akhras KS; Bittman RM; Krause SL
    Arch Intern Med; 2003 Jul; 163(13):1543-8. PubMed ID: 12860576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism.
    Parthasarathy HK; Ménard J; White WB; Young WF; Williams GH; Williams B; Ruilope LM; McInnes GT; Connell JM; MacDonald TM
    J Hypertens; 2011 May; 29(5):980-90. PubMed ID: 21451421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
    Germino FW
    Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients.
    Flack JM; Oparil S; Pratt JH; Roniker B; Garthwaite S; Kleiman JH; Yang Y; Krause SL; Workman D; Saunders E
    J Am Coll Cardiol; 2003 Apr; 41(7):1148-55. PubMed ID: 12679215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: systematic review and meta-analysis.
    Pelliccia F; Patti G; Rosano G; Greco C; Gaudio C
    Int J Cardiol; 2014 Nov; 177(1):219-28. PubMed ID: 25499383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
    Ando K; Ohtsu H; Uchida S; Kaname S; Arakawa Y; Fujita T;
    Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
    Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
    Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
    Epstein M; Williams GH; Weinberger M; Lewin A; Krause S; Mukherjee R; Patni R; Beckerman B
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension.
    White WB; Carr AA; Krause S; Jordan R; Roniker B; Oigman W
    Am J Cardiol; 2003 Jul; 92(1):38-42. PubMed ID: 12842242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
    Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
    Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial.
    Calhoun DA; White WB; Krum H; Guo W; Bermann G; Trapani A; Lefkowitz MP; Ménard J
    Circulation; 2011 Nov; 124(18):1945-55. PubMed ID: 21986283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
    Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD;
    Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.
    Pelliccia F; Rosano G; Patti G; Volterrani M; Greco C; Gaudio C
    Int J Cardiol; 2015 Dec; 200():8-11. PubMed ID: 25466561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study.
    Saruta T; Kageyama S; Ogihara T; Hiwada K; Ogawa M; Tawara K; Gatlin M; Garthwaite S; Bittman R; Patrick J
    J Clin Hypertens (Greenwich); 2004 Apr; 6(4):175-83; quiz 184-5. PubMed ID: 15073471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study.
    Luque Otero M; Martell Claros N;
    Clin Ther; 2005 Feb; 27(2):166-73. PubMed ID: 15811479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.